Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

12.41 -0.40 (-3.12%)
Streaming Delayed Price Updated: 11:53 AM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients
New data from Stoke Therapeutics' STK-001 studies reveal significant reductions in seizures and cognitive improvements in children with Dravet syndrome. STK-001 demonstrates promise as a well-tolerated... 
Via Benzinga
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
NeuBase Therapeutics stock is down on Tuesday as NBSE investors react to details concerning an upcoming special shareholder meeting. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Is Check-Cap (CHEK) Stock Up 44% Today?
Check-Cap stock is up on Tuesday with heavy trading as CHEK investors react to news of a business combination with Nobul AI. 
Via InvestorPlace
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
The Latest Analyst Ratings for Stoke Therapeutics
 
Via Benzinga
Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket
Shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) rose sharply in today’s pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001 
Via Benzinga
Why Is Stoke Therapeutics (STOK) Stock Up 99% Today?
Stoke Therapeutics stock is up on Tuesday as STOK shares see heavy trading alongside recent positive clinical trial data. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers on Tuesday as we check out all of the hottest news moving shares this morning! 
Via InvestorPlace
STOK Stock Earnings: Stoke Therapeutics Beats EPS, Misses Revenue for Q4 2023
STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Stoke Therapeutics Stock Rockets On Phase 1/2a Data: Here's Why
Stoke Therapeutics reported its fourth-quarter financial results and announced Phase 1/2a end of study data after the bell Monday. The company reported quarterly losses of 60 cents per share which beat... 
Via Benzinga
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money. 
Via InvestorPlace
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Appoints Ian Smith to its Board of Directors
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
From Stoke Therapeutics, Inc.
Via Business Wire
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
This small-cap biotech might be a hidden gem. 
Via The Motley Fool
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Stoke Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.